Menashe Elazar

Title: Menashe Elazar: Innovator in Anti-HCV Research

Introduction

Menashe Elazar is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of virology, particularly in the development of methods for identifying anti-HCV agents. His work is crucial in the ongoing battle against hepatitis C virus (HCV) infections.

Latest Patents

Menashe Elazar holds a patent titled "Methods and compositions for identifying anti-HCV agents." This invention provides innovative methods and compositions for identifying agents that can treat infections caused by viruses encoding a nucleotide-binding NS4B protein. The methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent and determining the effect of the candidate agent on various activities of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is classified as an anti-viral agent, specifically an anti-HCV agent. The invention also includes a polynucleotide encoding a modified NS4B polypeptide, which has potential therapeutic applications.

Career Highlights

Menashe Elazar is affiliated with Leland Stanford Junior University, where he continues to advance his research in virology. His work has led to the development of important methodologies that can be utilized in therapeutic and screening applications for HCV and related viruses.

Collaborations

Menashe has collaborated with esteemed colleagues such as Jeffrey S. Glenn and Shirit Einav. These collaborations have further enhanced the impact of his research in the scientific community.

Conclusion

Menashe Elazar's contributions to the field of anti-HCV research are invaluable. His innovative methods and compositions pave the way for new therapeutic options in combating viral infections.